Assessment Status |
NCPE Assessment Process Complete |
HTA ID |
- |
Drug |
Denosumab |
Brand |
Xgeva® |
Indication |
For the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland |
Full pharmacoeconomic assessment commissioned by HSE |
15/08/2011 |
NCPE assessment completed |
08/12/2011 |
NCPE assessment outcome |
Denosumab (Xgeva®) is considered a cost-effective therapy for the prevention of skeletal-related events in adults with bone metastases from solid tumours in the Irish healthcare setting. |